Ka Hou Christien Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ka Hou Christien Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gary Tse
School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
7 shared publications - Bryan Py Yan
The Chinese University of Hong Kong
5 shared publications - Aaron Jesuthasan
Department of Neurology, Addenbrooke’s Hospital, Cambridge, UK
3 shared publications - Christy K. Y. Chan
School of Public of Health Sciences, University of Waterloo , Waterloo, ON
3 shared publications - Ming-Zher Poh
Google Research, Cambridge, USA
3 shared publications - Olivia Tl To
Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong and Prince of Wales Hospital, Hong Kong, China (Hong Kong)
3 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by SAGE Publications in Rare Tumors
- Vol. 17
Efficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour
Solitary fibrous tumours (SFT) are very rare mesenchymal neoplasms. While surgery remains a standard treatment for localised disease, effective and long term treatment options for metastatic disease are lacking, making the use of aldoxorubicin a novel and promising systemic treatment in SFTs. We present a 30-year-old male who underwent surgical resection for a solitary fibrous tumour of the right leg. Postoperative imaging revealed metastatic disease in the liver and left upper quadrant. He was initially treated with pazopanib but experienced disease progression after 24 weeks. The patient was then enrolled on a phase III trial evaluating aldoxorubicin for advanced soft tissue sarcomas and received 350 mg/m 2 (260 mg/m 2 doxorubicin equivalent) intravenously every 21 days, cumulative dose being 9100 mg/m 2 . Treatment was well tolerated, with manageable toxicities including alopecia, leukopenia, mucositis, and grade 3 neutropenia requiring G-CSF support. Notably, serial echocardiograms showed no evidence of cardiotoxicity, with a preserved ejection fraction (56–65%). He completed 26 cycles with stable disease, followed by a 7-month treatment break before receiving compassionate-use aldoxorubicin. Disease stability persisted for 6 months until progression, which was treated with radiotherapy. Three months later, systemic progression led to treatment discontinuation. This case illustrates the favourable cardiac safety profile of aldoxorubicin and efficacy in solitary fibrous tumours.
- 1 June 2025
- Published by SAGE Publications in Rare Tumors
- Vol. 17
Open AccessEfficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour
Solitary fibrous tumours (SFT) are very rare mesenchymal neoplasms. While surgery remains a standard treatment for localised disease, effective and long term treatment options for metastatic disease are lacking, making the use of aldoxorubicin a novel and promising systemic treatment in SFTs. We present a 30-year-old male who underwent surgical resection for a solitary fibrous tumour of the right leg. Postoperative imaging revealed metastatic disease in the liver and left upper quadrant. He was initially treated with pazopanib but experienced disease progression after 24 weeks. The patient was then enrolled on a phase III trial evaluating aldoxorubicin for advanced soft tissue sarcomas and received 350 mg/m 2 (260 mg/m 2 doxorubicin equivalent) intravenously every 21 days, cumulative dose being 9100 mg/m 2 . Treatment was well tolerated, with manageable toxicities including alopecia, leukopenia, mucositis, and grade 3 neutropenia requiring G-CSF support. Notably, serial echocardiograms showed no evidence of cardiotoxicity, with a preserved ejection fraction (56–65%). He completed 26 cycles with stable disease, followed by a 7-month treatment break before receiving compassionate-use aldoxorubicin. Disease stability persisted for 6 months until progression, which was treated with radiotherapy. Three months later, systemic progression led to treatment discontinuation. This case illustrates the favourable cardiac safety profile of aldoxorubicin and efficacy in solitary fibrous tumours.
- Open Access
- 2 November 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 21 (1) , 65-79
Acute ischemic stroke management: concepts and controversies.A narrative review
Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still...
- 2 November 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 21 (1) , 65-79
Open AccessAcute ischemic stroke management: concepts and controversies.A narrative review
Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still...
- 31 May 2020
- Published by Wiley in Arthritis Care & Research
- Vol. 73 (9) , 1306-1311
Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice
Objective: To show the safety and efficacy of subcutaneous (SC) methotrexate (MTX) compared to oral MTX, alternative disease‐modifying antirheumatic drugs (DMARDs) monotherapy, biologic monotherapy, and combinations (conventional and biologic combination groups) in routine clinical practice.Methods: Clinical and laboratory data were retrospectively analyzed for rheumatology clinic attendances at a large Northeast England hospital trust between January 2014 and January 2018. Rates of adverse events and stop events (transaminitis [serum alanine aminotransferase level of >80 units/liter] or neutropenia [neutrophil count of 9/liter]) were calculated, with adjustment for duration of DMARD exposure.Results: In the present study, 8,394 patients received DMARDs, with 2,093 patients receiving oral MTX and 949 patients receiving SC MTX. The median dose was 15 mg (interquartile range [IQR] 10–20 mg) for oral MTX, and 20 mg (IQR 15–25 mg) for SC MTX (P < 0.0001). Continuation rates were higher for SC MTX therapy when adjusted for follow‐up duration, with a rate ratio (RR) of 1.54 (95% confidence interval [95% CI] 1.40–1.70) (P < 0.0001). For the time period assessed, 2,382 patients experienced 4,358 adverse events, with 1,711 incidents of transaminitis and 2,647 incidents of neutropenia recorded. Significantly fewer adverse events were observed in patients who received SC MTX monotherapy versus those who received biologic and combination DMARD therapies (P < 0.01). Compared to oral MTX, SC MTX was associated with a nonsignificant trend toward lower rates of neutropenia, but only a slightly higher rate of transaminitis (RR 1.26 [95% CI 1.07–1.48]) (P = 0.006), despite significantly higher doses of MTX.Conclusion: Subcutaneous MTX is safe in routine clinical practice. This is the largest study yet reported on SC MTX and provides observational data that SC MTX is continued longer and better tolerated in patients compared to other therapy groups, especially oral MTX.
- 31 May 2020
- Published by Wiley in Arthritis Care & Research
- Vol. 73 (9) , 1306-1311
Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice
Objective: To show the safety and efficacy of subcutaneous (SC) methotrexate (MTX) compared to oral MTX, alternative disease‐modifying antirheumatic drugs (DMARDs) monotherapy, biologic monotherapy, and combinations (conventional and biologic combination groups) in routine clinical practice.Methods: Clinical and laboratory data were retrospectively analyzed for rheumatology clinic attendances at a large Northeast England hospital trust between January 2014 and January 2018. Rates of adverse events and stop events (transaminitis [serum alanine aminotransferase level of >80 units/liter] or neutropenia [neutrophil count of 9/liter]) were calculated, with adjustment for duration of DMARD exposure.Results: In the present study, 8,394 patients received DMARDs, with 2,093 patients receiving oral MTX and 949 patients receiving SC MTX. The median dose was 15 mg (interquartile range [IQR] 10–20 mg) for oral MTX, and 20 mg (IQR 15–25 mg) for SC MTX (P < 0.0001). Continuation rates were higher for SC MTX therapy when adjusted for follow‐up duration, with a rate ratio (RR) of 1.54 (95% confidence interval [95% CI] 1.40–1.70) (P < 0.0001). For the time period assessed, 2,382 patients experienced 4,358 adverse events, with 1,711 incidents of transaminitis and 2,647 incidents of neutropenia recorded. Significantly fewer adverse events were observed in patients who received SC MTX monotherapy versus those who received biologic and combination DMARD therapies (P < 0.01). Compared to oral MTX, SC MTX was associated with a nonsignificant trend toward lower rates of neutropenia, but only a slightly higher rate of transaminitis (RR 1.26 [95% CI 1.07–1.48]) (P = 0.006), despite significantly higher doses of MTX.Conclusion: Subcutaneous MTX is safe in routine clinical practice. This is the largest study yet reported on SC MTX and provides observational data that SC MTX is continued longer and better tolerated in patients compared to other therapy groups, especially oral MTX.
- Open Access
- 15 February 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (2) , e11606
The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Smartphone applications capable of monitoring arrhythmias and heart rate are becoming widely available. These applications involve the use of photoplethysmography and recording through a hand-held external electrocardiographic recording device attached to the smartphone or wristband. This enables recordings to be obtained for analysis, which could be useful for screening, diagnosis and monitoring of heart rate and rhythm disorders. We conducted a narrative review into the use of smartphone devices by searching PubMed and Embase from their inception to April 2018. Potentially relevant papers were then compared against a checklist for relevance and reviewed independently for inclusion, with the focus on four allocated topics of i) smartphone monitoring, ii) atrial fibrillation, iii) heart rate and iv) heart rate variability.
- 15 February 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (2) , e11606
Open AccessThe Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Smartphone applications capable of monitoring arrhythmias and heart rate are becoming widely available. These applications involve the use of photoplethysmography and recording through a hand-held external electrocardiographic recording device attached to the smartphone or wristband. This enables recordings to be obtained for analysis, which could be useful for screening, diagnosis and monitoring of heart rate and rhythm disorders. We conducted a narrative review into the use of smartphone devices by searching PubMed and Embase from their inception to April 2018. Potentially relevant papers were then compared against a checklist for relevance and reviewed independently for inclusion, with the focus on four allocated topics of i) smartphone monitoring, ii) atrial fibrillation, iii) heart rate and iv) heart rate variability.
- Open Access
- 3 January 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (1) , e11616
Figure Correction: Resting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- 3 January 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (1) , e11616
Open AccessFigure Correction: Resting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- Open Access
- 18 July 2018
- Published by JMIR Publications Inc. in JMIR Preprints
The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review (Preprint)
BACKGROUND Mobile phone apps capable of monitoring arrhythmias and heart rate (HR) are increasingly used for screening, diagnosis, and monitoring of HR and rhythm disorders such as atrial fibrillation (AF). These apps involve either the use of (1) photoplethysmographic recording or (2) a handheld external electrocardiographic recording device attached to the mobile phone or wristband. OBJECTIVE This review seeks to explore the current state of mobile phone apps in cardiac rhythmology while highlighting shortcomings for further research. METHODS We conducted a narrative review of the use of mobile phone devices by searching PubMed and EMBASE from their inception to October 2018. Potentially relevant papers were then compared against a checklist for relevance and reviewed independently for inclusion, with focus on 4 allocated topics of (1) mobile phone monitoring, (2) AF, (3) HR, and (4) HR variability (HRV). RESULTS The findings of this narrative review suggest that there is a role for mobile phone apps in the diagnosis, monitoring, and screening for arrhythmias and HR. Photoplethysmography and handheld electrocardiograph recorders are the 2 main techniques adopted in monitoring HR, HRV, and AF. CONCLUSIONS A number of studies have demonstrated high accuracy of a number of different mobile devices for the detection of AF. However, further studies are warranted to validate their use for large scale AF screening.
- 18 July 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review (Preprint)
BACKGROUND Mobile phone apps capable of monitoring arrhythmias and heart rate (HR) are increasingly used for screening, diagnosis, and monitoring of HR and rhythm disorders such as atrial fibrillation (AF). These apps involve either the use of (1) photoplethysmographic recording or (2) a handheld external electrocardiographic recording device attached to the mobile phone or wristband. OBJECTIVE This review seeks to explore the current state of mobile phone apps in cardiac rhythmology while highlighting shortcomings for further research. METHODS We conducted a narrative review of the use of mobile phone devices by searching PubMed and EMBASE from their inception to October 2018. Potentially relevant papers were then compared against a checklist for relevance and reviewed independently for inclusion, with focus on 4 allocated topics of (1) mobile phone monitoring, (2) AF, (3) HR, and (4) HR variability (HRV). RESULTS The findings of this narrative review suggest that there is a role for mobile phone apps in the diagnosis, monitoring, and screening for arrhythmias and HR. Photoplethysmography and handheld electrocardiograph recorders are the 2 main techniques adopted in monitoring HR, HRV, and AF. CONCLUSIONS A number of studies have demonstrated high accuracy of a number of different mobile devices for the detection of AF. However, further studies are warranted to validate their use for large scale AF screening.
- Open Access
- 17 July 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Figure Correction: Resting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 17 July 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFigure Correction: Resting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- Open Access
- 1 January 2018
- Published by H1 Connect in Journal of Geriatric Cardiology
- Vol. 15 (11) , 710-712
Atypical electrocardiographic manifestations of ischemia: a case of dynamic Wellens patterns
- 1 January 2018
- Published by H1 Connect in Journal of Geriatric Cardiology
- Vol. 15 (11) , 710-712
Open AccessAtypical electrocardiographic manifestations of ischemia: a case of dynamic Wellens patterns
- Open Access
- 13 March 2017
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 5 (3) , e33
Resting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- 13 March 2017
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 5 (3) , e33
Open AccessResting and Postexercise Heart Rate Detection From Fingertip and Facial Photoplethysmography Using a Smartphone Camera: A Validation Study
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.